Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis

Brad Hall, Sawsan Alyafei, Sathishkumar Ramaswamy, Shruti Sinha, Maha El Naofal, Fatma Rabea, Bryan J. Killinger, Gary J. Latham, Ahmad Abou Tayoun
doi: https://doi.org/10.1101/2024.02.22.24303180
Brad Hall
1Asuragen, A Bio-Techne Brand, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sawsan Alyafei
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sathishkumar Ramaswamy
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shruti Sinha
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maha El Naofal
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fatma Rabea
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
3Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan J. Killinger
1Asuragen, A Bio-Techne Brand, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary J. Latham
1Asuragen, A Bio-Techne Brand, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmad Abou Tayoun
2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
4Center for Genomic Discovery, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, UAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Ahmad.Tayoun{at}dubaihealth.ae
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Spinal Muscular Atrophy (SMA) is one of the most common recessive disorders for which several life-saving treatment options are currently available. It is essential to establish universal SMA screening and diagnostic programs using scalable, cost-effective and accessible platforms to accurately identify all variation types, which is complicated by homologous SMN1 and SMN2 genes.

Methods We developed a dual-mode PCR-based target enrichment that generates 2.7 to 11.2 kb amplicons spanning SMN1 and SMN2 genes for any-length nanopore sequencing. We trained a variant calling model that utilizes paralog-specific sequences and read-depth data to accurately detect sequence and copy number variants specific to each gene.

Results We present results from the development, optimization, and external evaluation of this assay using over 750 samples, including cell lines, residual presumed normal blood donors, and patients with known SMN1 and SMN2 genotypes. The assay detects SNVs, indels, and CNVs with >98% accuracy across all sample sets, with a highly dynamic throughput range, relatively fast turnaround time, and limited hands-on-time. Together with the modest capital investment and consumable costs per sample, this assay can help increase access to SMA testing in low- and middle-income settings.

Conclusion We describe a PCR/Nanopore sequencing assay and a customized analysis pipeline for the comprehensive and accurate detection of variation at the SMA locus and demonstrate its scalability, cost-effectiveness, and potential for the universal implementation of SMA screening and diagnostic programs.

Human Genes SMN1 survival of motor neuron 1, telomeric HGNC:11117 SMN2 survival of motor neuron 2, centromeric HGNC:11118 CFTR CF transmembrane conductance regulator HGNC:1884

Competing Interest Statement

BH, BK, and GL are employees of Bio-Techne with stock and stock options in this company.

Funding Statement

This study received funding support from Asuragen and Oxford Nanopore Technologies in the form of reagents and consumables.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Dubai Health Authority Research Ethics Committee gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

  • Abbreviations

    SMA
    Spinal Muscular Atrophy
    SNVs
    Single nucleotide variants Indels, Insertions and deletions
    CNVs
    Copy number variants
    NGS
    Next generation sequencing
    US
    United States
    FDA
    Food and Drug Administration
    HRM
    High-resolution melt
    MLPA
    Multiplex ligation-dependent probe amplification
    ONT
    Oxford Nanopore Technologies
    PCR
    Polymerase chain reaction
    gDNA
    Genomic DNA
    NHGRI
    National Human Genome Research Institute
    NIGMS
    National Institute of General Medical Sciences
    ddPCR
    droplet digital PCR
    CE
    Capillary electrophoresis
    QC
    Quality control
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted February 23, 2024.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis
    Brad Hall, Sawsan Alyafei, Sathishkumar Ramaswamy, Shruti Sinha, Maha El Naofal, Fatma Rabea, Bryan J. Killinger, Gary J. Latham, Ahmad Abou Tayoun
    medRxiv 2024.02.22.24303180; doi: https://doi.org/10.1101/2024.02.22.24303180
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis
    Brad Hall, Sawsan Alyafei, Sathishkumar Ramaswamy, Shruti Sinha, Maha El Naofal, Fatma Rabea, Bryan J. Killinger, Gary J. Latham, Ahmad Abou Tayoun
    medRxiv 2024.02.22.24303180; doi: https://doi.org/10.1101/2024.02.22.24303180

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Genetic and Genomic Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (434)
    • Allergy and Immunology (758)
    • Anesthesia (222)
    • Cardiovascular Medicine (3313)
    • Dentistry and Oral Medicine (366)
    • Dermatology (282)
    • Emergency Medicine (479)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
    • Epidemiology (13397)
    • Forensic Medicine (19)
    • Gastroenterology (900)
    • Genetic and Genomic Medicine (5175)
    • Geriatric Medicine (482)
    • Health Economics (785)
    • Health Informatics (3283)
    • Health Policy (1145)
    • Health Systems and Quality Improvement (1198)
    • Hematology (432)
    • HIV/AIDS (1023)
    • Infectious Diseases (except HIV/AIDS) (14651)
    • Intensive Care and Critical Care Medicine (915)
    • Medical Education (478)
    • Medical Ethics (128)
    • Nephrology (525)
    • Neurology (4950)
    • Nursing (262)
    • Nutrition (734)
    • Obstetrics and Gynecology (888)
    • Occupational and Environmental Health (797)
    • Oncology (2530)
    • Ophthalmology (730)
    • Orthopedics (284)
    • Otolaryngology (348)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (547)
    • Pediatrics (1305)
    • Pharmacology and Therapeutics (552)
    • Primary Care Research (558)
    • Psychiatry and Clinical Psychology (4223)
    • Public and Global Health (7525)
    • Radiology and Imaging (1713)
    • Rehabilitation Medicine and Physical Therapy (1018)
    • Respiratory Medicine (981)
    • Rheumatology (480)
    • Sexual and Reproductive Health (500)
    • Sports Medicine (425)
    • Surgery (551)
    • Toxicology (72)
    • Transplantation (237)
    • Urology (206)